Stage 4 pancreatic cancer, also called metastatic pancreatic cancer, occurs when cancer cells spread beyond the pancreas to distant organs including the liver, lungs, or peritoneum, requiring comprehensive treatment strategies that balance life extension with quality of life preservation. TL;DR Only 15-20% of pancreatic cancers are diagnosed at potentially resectable stages, with most patients presenting with stage 4 disease requiring systemic therapy [1] FOLFIRINOX achieved

TL;DR Stage 4 pancreatic cancer treatment primarily involves systemic chemotherapy, with FOLFIRINOX achieving median survival of 11 months and gemcitabine/nab-paclitaxel regimens reaching 8.5 months [3] Only 49.1% of stage 4 pancreatic cancer patients receive systemic therapy, with significant disparities based on age, insurance status, and comorbidity scores [4] Targeted therapies including PARP inhibitors for BRCA mutations, NTRK inhibitors, and KRAS inhibitors provide pers